Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Calcif Tissue Int ; 115(2): 160-168, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38864922

ABSTRACT

Diabetic osteopathy is a frequent complication in patients with type 2 diabetes mellitus (T2DM). The association between T2DM and increased fracture risk has led to study the impact of new antidiabetic drugs on bone metabolism. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin mimetic drugs which have many pleiotropic properties. The relationship between GLP-1RAs and bone is very complex: while in vitro and animal studies have demonstrated a protective effect on bone, human studies are scarce. We led a 12 months longitudinal study evaluating bone changes in 65 patients withT2DM for whom a therapy with GLP-1RAs had been planned. Fifty-four T2DM patients completed the 12-month study period; of them, 30 had been treated with weekly dulaglutide and 24 with weekly semaglutide. One-year therapy with GLP-1RAs resulted in a significant reduction in weight and BMI. Bone mineral density (BMD), bone metabolism, trabecular bone score (TBS), adiponectin, and myostatin were evaluated before and after 12 months of GLP-1RAs therapy. After 12 months of therapy bone turnover markers and adiponectin showed a significant increase, while myostatin values showed a modest but significant reduction. BMD-LS by DXA presented a significant reduction while the reduction in BMD-LS by REMS was not significant and TBS values showed a marginal increase. Both DXA and REMS techniques showed a modest but significant reduction in femoral BMD. In conclusion, the use of GLP-1RAs for 12 months preserves bone quality and reactivates bone turnover. Further studies are needed to confirm whether GLP-1RAs could represent a useful therapeutic option for patients with T2DM and osteoporosis.


Subject(s)
Bone Density , Diabetes Mellitus, Type 2 , Glucagon-Like Peptide-1 Receptor , Glucagon-Like Peptides , Hypoglycemic Agents , Immunoglobulin Fc Fragments , Incretins , Humans , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/complications , Longitudinal Studies , Glucagon-Like Peptide-1 Receptor/agonists , Female , Middle Aged , Glucagon-Like Peptides/therapeutic use , Glucagon-Like Peptides/analogs & derivatives , Glucagon-Like Peptides/pharmacology , Male , Bone Density/drug effects , Hypoglycemic Agents/therapeutic use , Hypoglycemic Agents/pharmacology , Aged , Immunoglobulin Fc Fragments/therapeutic use , Incretins/therapeutic use , Recombinant Fusion Proteins/therapeutic use , Recombinant Fusion Proteins/pharmacology , Bone Diseases, Metabolic/drug therapy , Glucagon-Like Peptide-1 Receptor Agonists
2.
Nutrients ; 16(8)2024 Apr 12.
Article in English | MEDLINE | ID: mdl-38674837

ABSTRACT

Nowadays, the interest in the extraskeletal effects of vitamin D is growing. In the literature, its several possible actions have been confirmed. Vitamin D seems to have a regulatory role in many different fields-inflammation, immunity, and the endocrine system-and many studies would demonstrate a possible correlation between vitamin D and cardiovascular disease. In this paper, we deepened the relationship between vitamin D and dyslipidemia by reviewing the available literature. The results are not entirely clear-cut: on the one hand, numerous observational studies suggest a link between higher serum vitamin D levels and a beneficial lipid profile, while on the other hand, interventional studies do not demonstrate a significant effect. Understanding the possible relationship between vitamin D and dyslipidemia may represent a turning point: another link between vitamin D and the cardiovascular system.


Subject(s)
Dyslipidemias , Vitamin D Deficiency , Vitamin D , Humans , Dyslipidemias/blood , Vitamin D/blood , Vitamin D Deficiency/complications , Vitamin D Deficiency/blood , Cardiovascular Diseases/prevention & control , Cardiovascular Diseases/etiology , Lipids/blood
3.
Children (Basel) ; 10(12)2023 Nov 27.
Article in English | MEDLINE | ID: mdl-38136063

ABSTRACT

The present study aimed to evaluate the burden and management of fragility fractures in subjects with Rett syndrome. We searched all relevant medical literature from 1 January 1986 to 30 June 2023 for studies under the search term "Rett syndrome and fracture". The fracture frequency ranges from a minimum of 13.9% to a maximum of 36.1%. The majority of such fractures occur in lower limb bones and are associated with low bone mineral density. Anticonvulsant use, joint contractures, immobilization, low physical activity, poor nutrition, the genotype, and lower calcium and vitamin D intakes all significantly impair skeletal maturation and bone mass accrual in Rett syndrome patients, making them more susceptible to fragility fractures. This review summarizes the knowledge on risk factors for fragility fracture in patients with Rett syndrome and suggests a possible diagnostic and therapeutic care pathway for improving low bone mineral density and reducing the risk of fragility fractures. The optimization of physical activity, along with adequate nutrition and the intake of calcium and vitamin D supplements, should be recommended. In addition, subjects with Rett syndrome and a history of fracture should consider using bisphosphonates.

4.
J Imaging ; 9(10)2023 Oct 03.
Article in English | MEDLINE | ID: mdl-37888317

ABSTRACT

This study aimed to estimate the utility of the Radiofrequency Echographic Multispectrometry (REMS) approach in the assessment of bone mineral density (BMD) in subjects with osteogenesis imperfecta (OI). In 41 subjects (40.5 ± 18.7 years) with OI and in 36 healthy controls, we measured BMD at the lumbar spine (LS-BMD), femoral neck (FN-BMD) and total hip (TH-BMD), employing a dual-energy X-ray absorptiometry tool. Additionally, REMS scans were also performed at the lumbar and femoral sites. The presence and number of reported fractures were assessed in the study population. Patients characterized by a history of fragility fractures represented 84.5% of the study population. OI subjects showed significantly reduced BMD values both at the level of the lumbar spine and the femoral subregions (p < 0.01) compared to healthy controls when performed using both the DXA and the REMS method. Dividing OI patients on the basis of the Sillence classification, no differences were found between the LS-BMD values carried out using the DXA technique between the OI type I group and OI Type III and IV groups. On the contrary, the OI Type III and IV groups presented significantly lower values of both Trabecular Bone Score (TBS) and LS-BMD through REMS with respect to OI type I patients (p < 0.05). Based on the data of this study, it is possible to conclude that even the new REMS assessment, which does not use ionizing radiation, represents an excellent method for studying the bone status in subjects affected by OI.

5.
Diagnostics (Basel) ; 13(10)2023 May 09.
Article in English | MEDLINE | ID: mdl-37238151

ABSTRACT

Osteoporosis is a frequently occurring skeletal disease, and osteoporosis-related fractures represent a significant burden for healthcare systems. Dual-Energy X-ray Absorptiometry (DXA) is the most commonly used method for assessing bone mineral density (BMD). Today, particular attention is being directed towards new technologies, especially those that do not use radiation, for the early diagnosis of altered bone status. Radiofrequency Echographic Multi Spectrometry (REMS) is a non-ionizing technology that evaluates the bone status at axial skeletal sites by analyzing raw ultrasound signals. In this review, we evaluated the data on the REMS technique present in the literature. The literature data confirmed diagnostic concordance between BMD values obtained using DXA and REMS. Furthermore, REMS has adequate precision and repeatability characteristics, is able to predict the risk of fragility fractures, and may be able to overcome some of the limitations of DXA. In conclusion, REMS could become the method of choice for the assessment of bone status in children, in women of childbearing age or who are pregnant, and in several secondary osteoporosis conditions due to its good precision and replicability, its transportability, and the absence of ionizing radiation. Finally, REMS may allow qualitative and not just quantitative assessments of bone status.

6.
Aging Clin Exp Res ; 35(5): 1097-1105, 2023 May.
Article in English | MEDLINE | ID: mdl-36988828

ABSTRACT

BACKGROUND: Cardiovascular disease, osteoporosis and sarcopenia are very common age-related conditions. This study aimed at investigating the relationships of cardiac calcifications, as assessed by using GCCS with BMD, fragility fractures and sarcopenia in elderly subjects. METHODS: In a cohort of 106 subjects (age 70.4 ± 5.8 yrs) we measured lumbar (BMD-LS), femoral BMD (femoral neck: BMD-FN, total femur: BMD-TH) and body composition (BMD-WB) with Dual-energy X-ray Absorptiometry (DXA) method. We also evaluated the presence of sarcopenia on the basis of the EWGSOP Consensus. All subjects, simultaneously, underwent to a transthoracic color doppler echocardiography exam to assess the presence of cardiac calcifications. The degree of non coronaric cardiac calcifications was evaluated using the Global Cardiac Calcium Score (GCCS). RESULTS: The degree of cardiac calcification assessed by GCCS was significantly higher in osteoporotic patients (p < 0.001). Furthermore, an inverse correlation emerged between BMD and GCCS, statistical significance was found at lumbar spine and femoral sub-regions in female population (p < 0.01). Moreover by dividing population according to the presence of fragility fractures, we observed that GCCS values were significantly higher in subjects with fractures in respect of non-fractured ones (p < 0.05). Multiple regression models showed that BMD-LS and BMD-FT were independently associated with cardiac calcification. GCCS values were significantly associated with BMI and ASMM in women (p < 0.01 and p < 0.05, respectively) and with handgrip strength in men (p < 0.05). CONCLUSIONS: Our data confirm the presence of a relationship between cardiac calcifications and decreased BMD values. It's also the first study that relates sarcopenia and valvular calcifications.


Subject(s)
Fractures, Bone , Osteoporosis , Sarcopenia , Male , Humans , Female , Aged , Bone Density , Sarcopenia/diagnostic imaging , Sarcopenia/complications , Hand Strength , Osteoporosis/complications , Absorptiometry, Photon/methods , Fractures, Bone/complications , Femur Neck/diagnostic imaging , Lumbar Vertebrae/diagnostic imaging
7.
Front Endocrinol (Lausanne) ; 13: 1001065, 2022.
Article in English | MEDLINE | ID: mdl-36313775

ABSTRACT

In recent years, vitamin D has become the protagonist in many studies. From cardiology to oncology the spotlight was on this vitamin. While in the past it was considered for its important role in phospho-calcium metabolism and skeletal disorders; today by studying it better, thousands of scenarios and facets have opened up on this vitamin which is actually a hormone in all respects. There are authoritative studies that demonstrate its activity in vitro and in vivo on: carcinogenesis, inflammation, autoimmunity and endocrinopathies. Its role has been studied in type 1 and type 2 diabetes mellitus, in Hashimoto or Graves' thyroiditis and even in adrenal gland diseases. In fact, there are several studies that demonstrate the possible correlations between vitamin D and: Addison's disease, Cushing disease, hyperaldosteronism or adrenocortical tumors. Moreover, this fascinating hormone and adrenal gland even seem to be deeply connected by common genetic pathways. This review aimed to analyze the works that have tried to study the possible influence of vitamin D on adrenal diseases. In this review we analyze the works that have tried to study the possible influence of vita-min D on adrenal disease.


Subject(s)
Diabetes Mellitus, Type 2 , Hyperaldosteronism , Humans , Vitamin D , Adrenal Glands , Vitamins , Hormones
8.
Indian J Endocrinol Metab ; 26(6): 518-523, 2022.
Article in English | MEDLINE | ID: mdl-39005514

ABSTRACT

Bone fragility is increasingly recognized as an important complication of diabetes mellitus (DM), and both type 1 (T1DM) and type 2 (T2DM) diabetes are associated with a higher risk of fracture. The causes of bone fragility in diabetic patients are not yet fully understood; probably they are linked to low bone mineral density (BMD), poor bone quality due to the alterations in bone remodelling, microarchitecture and composition of the bone matrix. Quantitative ultrasound (QUS) is a validated, low-cost and free ionizing radiation alternative to DXA measurement of BMD for the assessment of fracture risk. The results obtained by using QUS in T1DM and T2DM have been summarized and reported in this review. QUS technique presents some benefits but also some limits. These limits could be overcome by radiofrequency echographic multispectrometry (REMS) that is a non-ionizing technology recently introduced for the assessment of bone status that can also calculate parameters related to bone quality and strength. Therefore, REMS may represent a promising approach to evaluate bone status and fragility fracture risk in DM subjects.

SELECTION OF CITATIONS
SEARCH DETAIL
...